Skip to main content

GALAPAGOS NV

corporate_fare Company Profile

GALAPAGOS NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed GLPG - Latest Insights

GLPG
Apr 29, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
7
GLPG
Mar 31, 2026, 1:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
GLPG
Mar 30, 2026, 9:41 PM EDT
Filing Type: 6-K
Importance Score:
9
GLPG
Mar 30, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
8
GLPG
Mar 26, 2026, 4:02 PM EDT
Filing Type: 20-F
Importance Score:
9
GLPG
Mar 23, 2026, 6:25 PM EDT
Source: GlobeNewswire
Importance Score:
9
GLPG
Mar 17, 2026, 5:26 PM EDT
Filing Type: 6-K
Importance Score:
7
GLPG
Mar 06, 2026, 4:28 PM EST
Filing Type: 6-K
Importance Score:
7
GLPG
Mar 05, 2026, 4:28 PM EST
Filing Type: 6-K
Importance Score:
7
GLPG
Feb 23, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
8
GLPG
Feb 19, 2026, 4:43 PM EST
Filing Type: 6-K
Importance Score:
7
GLPG
Feb 17, 2026, 6:19 AM EST
Filing Type: 6-K
Importance Score:
7
GLPG
Jan 05, 2026, 4:57 PM EST
Filing Type: 6-K
Importance Score:
8